Wang K, Jin LY, Zhang QG. Prognostic value of liver outcome score and hemoglobin in autoimmune liver disease overlap syndromes. World J Hepatol 2025; 17(2): 103345 [DOI: 10.4254/wjh.v17.i2.103345]
Corresponding Author of This Article
Qin-Guo Zhang, MD, Professor, Department of Hepatobiliary Surgery, Zhuji People’s Hospital, No. 1 Wenwei Road, Datang Street, Zhuji 311800, Zhejiang Province, China. zhangqg8@aliyun.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Hepatol. Feb 27, 2025; 17(2): 103345 Published online Feb 27, 2025. doi: 10.4254/wjh.v17.i2.103345
Prognostic value of liver outcome score and hemoglobin in autoimmune liver disease overlap syndromes
Kai Wang, Lei-Yang Jin, Qin-Guo Zhang
Kai Wang, Lei-Yang Jin, Department of Hepatobiliary Surgery, Zhuji People’s Hospital, Zhuji 311800, Zhejiang Province, China
Qin-Guo Zhang, Department of General Surgery, Zhuji Sixth People’s Hospital, Zhuji 311800, Zhejiang Province, China
Author contributions: Wang K and Jin LY contributed to conceptualized, designed the study and created the artwork; Zhang QG contributed to software, conducted the literature review, performed the data analysis and interpretation, and reviewed and edited the final manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest related to this article.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Qin-Guo Zhang, MD, Professor, Department of Hepatobiliary Surgery, Zhuji People’s Hospital, No. 1 Wenwei Road, Datang Street, Zhuji 311800, Zhejiang Province, China. zhangqg8@aliyun.com
Received: November 18, 2024 Revised: January 3, 2025 Accepted: January 14, 2025 Published online: February 27, 2025 Processing time: 96 Days and 18 Hours
Abstract
This letter addresses the study by Jayabalan et al, which underscores the liver outcome score (LOS) and hemoglobin (Hb) as key prognostic markers for patients with autoimmune liver disease overlap syndromes (AILDOS), with particular relevance to the autoimmune hepatitis-primary biliary cholangitis (AIH-PBC) subgroup. The findings indicate that an LOS threshold of 6 achieves high sensitivity and specificity in predicting liver-related mortality among AIH-PBC patients. Moreover, low Hb levels emerge as a significant mortality predictor across all AILDOS cases. These results contribute valuable perspectives on risk stratification in AILDOS, highlighting the promise of non-invasive prognostic tools. Future studies with larger cohorts are needed to substantiate LOS and Hb as robust markers for clinical application.
Core Tip: The liver outcome score (LOS) and hemoglobin (Hb) levels are important prognostic markers in autoimmune liver disease overlap syndromes (AILDOS), especially within the autoimmune hepatitis-primary sclerosing cholangitis subgroup. LOS demonstrates a high degree of predictive accuracy for liver-related mortality, positioning it as a valuable tool for risk stratification where traditional scoring systems may be insufficient. Additionally, consistently low Hb levels correlate with increased mortality across AILDOS cases, highlighting the prognostic impact of anemia in these patients. These findings indicate that non-invasive markers like LOS and Hb could improve clinical decision-making for managing complex liver diseases. Further research with larger cohorts is needed to validate LOS and Hb as effective prognostic tools in AILDOS management.
